Viewing Study NCT03507166


Ignite Creation Date: 2025-12-24 @ 4:13 PM
Ignite Modification Date: 2026-01-04 @ 2:49 AM
Study NCT ID: NCT03507166
Status: COMPLETED
Last Update Posted: 2019-08-21
First Post: 2018-04-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
Sponsor: RemeGen Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module